Oncolytic Urabe Mumps Virus: A Promising Virotherapy for Triple Negative Breast Cancer

Two oncolytic Urabe mumps virus clinical trial virus stock (MuV-U-Japan) isolates, MuV-UA and MuV-UC, potently killed a panel of established human breast cancer cell lines in vitro, significantly extended survival of nude mice with human TNBC MDA-MB-231 tumor xenografts in vivo, and demonstrated significant killing activity against breast cancer patient derived xenograft cell lines grown as 3D-organoids.